About Arrowhead Pharmaceuticals (ARWR)

Arrowhead Pharmaceuticals Inc. (ARWR) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. The company specializes in the discovery and development of RNAi-based drugs that target and silence specific genes involved in various diseases. Arrowhead's proprietary technology platform, called Dynamic Polyconjugates (DPCs), allows for the efficient delivery of RNAi molecules to specific tissues, enabling targeted gene silencing and disease modification. The company's pipeline includes multiple clinical-stage candidates targeting different indications, such as liver diseases, cardio-metabolic disorders, and various oncology indications.

Arrowhead Pharmaceuticals Inc. (ARWR) quote: ARWR is currently trading at $75.20 per share. The stock has a market capitalization of $8.5 billion. Over the past year, ARWR has experienced significant growth, with a 52-week range of $23.46 to $88.20. As of today, the stock is trading near its 52-week high. The trading volume for ARWR is relatively high, indicating strong investor interest. The PEG ratio for ARWR is not currently available. When comparing ARWR to its industry peers, the stock has outperformed with its strong growth trajectory. Arrowhead Pharmaceuticals Inc. is well-positioned in the RNAi therapeutics space.